

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



MOLECULAR DIAGNOSTICS FOR CANCER. MARKETS FORECASTS BY CANCER TYPE, PRODUCT AND PLACE WITH EXECUTIVE AND CONSULTANT GUIDES AND CUSTOMIZATION. 2021 TO 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Pandemic.....	19
2	Guide for Executives, Marketing, Sales and Business Development Staff	22
3	Guide for Management Consultants and Investment Advisors.....	23
4	Introduction and Market Definition	24
4.1	What is Molecular Diagnostics.....	25
4.2	The Diagnostics Revolution.....	25
4.3	Market Definition.....	27
4.3.1	Revenue Market Size.....	27
4.4	Methodology.....	28
4.4.1	Authors	28
4.4.2	Sources.....	28
4.5	U.S. Medical Market and laboratory Testing - Perspective.....	29
4.5.1	U.S. Medicare Expenditures for Laboratory Testing	29
5	Market Overview.....	31
5.1	Market Participants	32
5.1.1	Academic Research Lab	33
5.1.2	Diagnostic Test Developer.....	33
5.1.3	Genomic Instrumentation Supplier	33
5.1.4	Cell Separation and Viewing Instrumentation Supplier.	34
5.1.5	Pharmaceutical/Reagent Supplier	34
5.1.6	Independent Testing Lab.....	34
5.1.7	Public National/regional lab	34
5.1.8	Hospital lab	35
5.1.9	Physician Lab	35

5.1.10	Audit Bodies	35
5.1.11	Certification Body.....	36
5.2	Market Segments	37
5.2.1	Traditional Market Segmentation.....	37
5.2.2	Laboratory Focus and Segmentation.....	38
5.3	Industry Structure.....	40
5.3.1	Hospital Testing Share	40
5.3.2	Economies of Scale.....	40
5.3.3	Physician Office Lab's.....	42
5.3.4	Physician's and POCT	42
6	Market Trends	43
6.1	Factors Driving Growth	44
6.1.1	New Diagnostics Create New Markets.....	44
6.1.2	New Roles for Diagnostics.....	45
6.1.3	Longevity and Outcomes.....	45
6.1.4	Expanding the Pharmaceutical Toolbox.....	46
6.1.5	Regulatory Retreat	46
6.2	Factors Limiting Growth	47
6.2.1	Falling Prices.....	47
6.2.2	Lower Costs.....	48
6.2.3	COVID Pandemic.....	48
6.2.4	Wellness has a Downside	48
6.3	Instrumentation and Automation	49
6.3.1	Instruments Key to Market Share	49
6.3.2	Bioinformatics Plays a Role	49
6.4	Diagnostic Technology Development	50
6.4.1	Next Generation Sequencing	51
6.4.2	Shifting Role of Diagnostics.....	53

6.4.3	Multiplexing and Foundation One	54
6.4.4	Pharmacogenomics Technology	54
6.4.5	Whole Genome Sequencing	55
6.4.6	Gene Editing and Gene Therapy.....	55
7	Molecular Diagnostics Recent Developments	57
7.1	Recent Developments – Importance and How to Use This Section	58
7.1.1	Importance of These Developments	58
7.1.2	How to Use This Section.....	58
7.2	Nucleix to Invest in Early-Stage Lung Cancer Dx.....	58
7.3	Invitae to Acquire Genosity for \$200M.....	60
7.4	Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test	61
7.5	Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience	62
7.6	Natera Revenues Grow 35 Percent.....	63
7.7	AnchorDx Closes \$40M Financing Round	63
7.8	Exact Sciences Strategy for End-to-End Cancer Testing	64
7.9	Genomics England: Whole Genome Sequencing for Cancer Patients to Launch	67
7.10	Singlera Genomics Closes \$150M Funding for Cancer Screening	70
7.11	Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform	71
7.12	Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test	72
7.13	Metastatic Cancer Markers Identified in Clinical WGS Study.....	72
7.14	Stitch Bio Bets on CRISPR Tech	75
7.15	Bayer, LifeLabs Launch Free NTRK Genetic Testing Program	79
7.16	Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx	79
7.17	Progress, Challenges in Liquid Biopsy Reimbursement.....	80
7.18	Israeli Startup Curesponse Raises \$6M	84
7.19	Coronavirus Pandemic Bites into European Cancer Research	84
7.20	Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy ...	87
7.21	Combining CRISPR and Nanopore Sequencing	88

7.22	Liquid Biopsy Detects Cancer Early via Cell Clusters.....	90
7.23	Roche, Illumina unveil 15-year cancer diagnostic tie-up	92
7.24	Saga, Servier Sign Liquid Biopsy Services Deal.....	93
7.25	Home urine test could revolutionize diagnosis of prostate cancer	94
7.26	Cancer Gene Tests Cost-Effective for Breast Cancer Patients.....	95
7.27	Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay.....	96
7.28	OncoCyte to Buy Cancer Testing Company Razor Genomics.....	97
7.29	Blood Test May Eliminate Need for Exploratory Surgery.....	98
7.30	NGS Cancer Panel Receives New York State Conditional Approval	99
7.31	Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb	100
8	Profiles of Key MDx Companies	102
8.1	10x Genomics, Inc.....	103
8.2	Abbott Diagnostics	104
8.3	AccuraGen Inc.	105
8.4	Adaptive Biotechnologies.....	106
8.5	Aethlon Medical	107
8.6	Agena Bioscience, Inc.	108
8.7	Agilent.....	110
8.8	Anchor Dx.....	112
8.9	ANGLE plc.....	113
8.10	ApoCell, Inc.....	114
8.11	ArcherDx, Inc.	115
8.12	ARUP Laboratories.....	116
8.13	Asuragen.....	118
8.14	AVIVA Biosciences	119
8.15	Baylor Miraca Genetics Laboratories	120
8.16	Beckman Coulter, Inc.	121
8.17	BGI Genomics Co. Ltd	123

8.18	Bioarray Genetics.....	125
8.19	Biocartis.....	126
8.20	Biocept, Inc.....	127
8.21	Biodesix Inc.	128
8.22	BioFluidica.....	129
8.23	BioGenex	130
8.24	Biolidics Ltd.....	132
8.25	bioMérieux Diagnostics.....	133
8.26	Bioneer Corporation	134
8.27	Bio-Rad Laboratories, Inc.....	136
8.28	Bio-Reference Laboratories.....	138
8.29	Bio-Techne	139
8.30	Bioview	140
8.31	Bolidics	141
8.32	Boreal Genomics.....	142
8.33	Bristol-Myers Squibb.....	143
8.34	Cancer Genetics.....	144
8.35	Caris Molecular Diagnostics	145
8.36	CellMax Life	146
8.37	Cepheid (now Danaher)	147
8.38	Charles River Laboratories.....	148
8.39	Chronix Biomedical	149
8.40	Circulogene.....	150
8.41	Clinical Genomics	151
8.42	Cynvenio.....	152
8.43	Cytolumina Technologies Corp.	153
8.44	CytoTrack.....	154
8.45	Datar Cancer Genetics Limited.....	155

8.46	Diagnologix LLC.....	156
8.47	Diasorin S.p.A.....	157
8.48	Enzo Life Sciences, Inc.	158
8.49	Epic Sciences.....	159
8.50	Epigenomics AG.....	160
8.51	Eurofins Scientific	161
8.52	Exosome Diagnostics	163
8.53	Exosome Sciences.....	164
8.54	Fabric Genomics	165
8.55	Fluidigm Corp	166
8.56	Fluxion Biosciences.....	167
8.57	Foundation Medicine	168
8.58	Freenome.....	169
8.59	FUJIFILM Wako Diagnostics.....	170
8.60	GeneFirst Ltd.....	171
8.61	Genetron Health (Beijing) Co., Ltd.	172
8.62	Genomic Health.....	173
8.63	GenomOncology.....	174
8.64	GILUPI Nanomedizin.....	175
8.65	Grail, Inc.....	176
8.66	Guardant Health	177
8.67	HalioDx	178
8.68	HansaBiomed	179
8.69	HeiScreen.....	180
8.70	Helomics.....	181
8.71	Horizon Discovery	182
8.72	HTG Molecular Diagnostics	183
8.73	iCellate	184

8.74	Illumina	185
8.75	Incell Dx.....	186
8.76	Inivata	187
8.77	Integrated Diagnostics	188
8.78	Invivogen	189
8.79	Invivoscribe	190
8.80	Janssen Diagnostics	191
8.81	MDNA Life SCIENCES, Inc.....	192
8.82	MDx Health	193
8.83	Menarini Silicon Biosystems.....	194
8.84	Millipore Sigma	195
8.85	Miltenyi Biotec	196
8.86	MIODx.....	197
8.87	miR Scientific.....	198
8.88	Molecular MD	199
8.89	MyCartis	200
8.90	Myriad Genetics/Myriad RBM	201
8.91	NantHealth, Inc.	202
8.92	Natera	203
8.93	NeoGenomics	204
8.94	New Oncology	205
8.95	Novogene Bioinformatics Technology Co., Ltd.....	206
8.96	Oncocyte.....	208
8.97	OncoDNA	209
8.98	Ortho Clinical Diagnostics	210
8.99	Oxford Nanopore Technologies	211
8.100	Panagene.....	213
8.101	Perkin Elmer.....	214

8.102	Personal Genome Diagnostics.....	215
8.103	Personalis.....	216
8.104	Precipio	217
8.105	PrecisionMed	218
8.106	Promega	219
8.107	Qiagen Gmbh	221
8.108	Rarecells SAS.....	223
8.109	RareCyte.....	224
8.110	Roche Molecular Diagnostics	226
8.111	ScreenCell	228
8.112	Sense Biodetection.	229
8.113	Serametrix	230
8.114	Siemens Healthineers	231
8.115	Silicon Biosystems.....	233
8.116	simfo GmbH	234
8.117	Singlera Genomics Inc.....	235
8.118	Singulomics	236
8.119	SkylineDx	237
8.120	Stratos Genomics	238
8.121	Sysmex Inostics.....	239
8.122	Tempus Labs, Inc.	240
8.123	Thermo Fisher Scientific Inc.....	241
8.124	Thrive Earlier Detection	243
8.125	Todos Medical	244
8.126	Trovagene.....	245
8.127	Volition	246
8.128	Vortex Biosciences	247
9	The Global Market for MDx Cancer	248

9.1	MDx Cancer – Global Market Overview by Country	249
9.1.1	Table – Global Market by Country.....	249
9.1.2	Chart - Global Market by Country	250
9.2	Global Market by Cancer Type - Overview.....	251
9.2.1	Table – Global Market by Cancer Type	251
9.2.2	Chart – Global Market by Cancer Type – Base/Final Comparison	252
9.2.3	Chart – Global Market by Cancer Type – Base Year	253
9.2.4	Chart – Global Market by Cancer Type –Final Year.....	254
9.2.5	Chart – Global Market by Cancer Type – Share by Year	255
9.2.6	Chart – Global Market by Cancer Type – Segment Growth	256
9.3	Global Market by Product Type - Overview	257
9.3.1	Table – Global Market by Product Type.....	257
9.3.2	Chart – Global Market by Product Type – Base/Final Comparison	258
9.3.3	Chart – Global Market by Product Type – Base Year.....	259
9.3.4	Chart – Global Market by Product Type –Final Year	260
9.3.5	Chart – Global Market by Product Type – Share by Year.....	261
9.3.6	Chart – Global Market by Product Type – Segment Growth.....	262
9.4	Global Market by Place - Overview	263
9.4.1	Table – Global Market by Place.....	263
9.4.2	Chart – Global Market by Place – Base/Final Comparison	264
9.4.3	Chart – Global Market by Place – Base Year.....	265
9.4.4	Chart – Global Market by Place –Final Year.....	266
9.4.5	Chart – Global Market by Place – Share by Year.....	267
9.4.6	Chart – Global Market by Place – Segment Growth	268
10	Global Market by Cancer Type.....	269
10.1	MDx Breast Cancer	270
10.1.1	Table Breast Cancer Testing – by Country	270
10.1.2	Chart - Breast Cancer Testing Growth.....	271

10.2	MDx Colorectal Cancer	272
10.2.1	Table Colorectal Cancer Testing – by Country.....	272
10.2.2	Chart - Colorectal Cancer Testing Growth.....	273
10.3	MDx Cervical Cancer	274
10.3.1	Table Cervical Cancer Testing – by Country	274
10.3.2	Chart - Cervical Cancer Testing Growth.....	275
10.4	MDx Lung Cancer	276
10.4.1	Table Lung Cancer Testing – by Country	276
10.4.2	Chart - Lung Cancer Testing Growth.....	277
10.5	MDx Prostate.....	278
10.5.1	Table Prostate Testing – by Country.....	278
10.5.2	Chart - Prostate Testing Growth	279
10.6	MDx Melanoma Cancer.....	280
10.6.1	Table Melanoma Cancer Testing – by Country.....	280
10.6.2	Chart - Melanoma Cancer Testing Growth	281
10.7	MDx Blood.....	282
10.7.1	Table Blood Testing – by Country	282
10.7.2	Chart - Blood Testing Growth	283
10.8	MDx Companion Dx Development	284
10.8.1	Table Companion Dx Development – by Country.....	284
10.8.2	Chart - Companion Dx Development Growth	285
10.9	MDx Other Cancer.....	286
10.9.1	Table Other Cancer Testing – by Country.....	286
10.9.2	Chart - Other Cancer Testing Growth	287
11	Global Market by Product Type	288
11.1	MDx Instruments	289
11.1.1	Table Instruments – by Country	289
11.1.2	Chart - Instruments Growth.....	290

- 11.2 MDx Reagents 291
 - 11.2.1 Table Reagents – by Country 291
 - 11.2.2 Chart - Reagents Growth 292
- 11.3 MDx Software and Services..... 293
 - 11.3.1 Table Software and Services – by Country..... 293
 - 11.3.2 Chart - Software and Services Growth..... 294
- 12 Global Market by Place295
 - 12.1 MDx Clinical Laboratory 296
 - 12.1.1 Table Clinical Laboratory – by Country 296
 - 12.1.2 Chart - Clinical Laboratory Growth 297
 - 12.2 MDx Pharmaceutical 298
 - 12.2.1 Table Pharmaceutical – by Country 298
 - 12.2.2 Chart - Pharmaceutical Growth 299
 - 12.3 MDx Research 299
 - 12.3.1 Table Research – by Country 300
 - 12.3.2 Chart - Research Growth..... 301
- 13 Cancer Treatment and Trials.....302
 - 13.1 FDA Cancer Drug Approvals by Year..... 303
 - 13.2 Clinical Trials Started 2010 to 2016 304
 - 13.3 Prevalence of Cancer Treatments – 2015..... 305
- 14 Appendices.....306
 - 14.1 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule . 306
 - 14.2 FDA Approved Human Genetic Tests..... 367
 - 14.3 FDA Approved Microbial Tests 371
 - 14.4 FDA Approved Pharmacogenomics Tests 380

Table of Tables

Table 1 Lab Spending 2014 to 2024	30
Table 2 Market Players by Type	32
Table 3 Clinical Laboratory Departments and Segments	37
Table 4 Laboratory Management Focus – Different Approaches	38
Table 5 Key Segmentation Variables Going Forward.....	39
Table 6 Five Factors Driving Growth	44
Table 7 Four Factors Limiting Growth	47
Table 8 Key Diagnostic Laboratory Technology Trends	50
Table 9 Next Generation Sequencing Technologies – Speed and Cost	51
Table 10 - Global MDx Cancer Market by Region.....	249
Table 11 Global Market by Cancer Type	251
Table 12 Global Market by Product Type	257
Table 13 Global Market by Place.....	263
Table 14 MDx Breast Cancer by Country	270
Table 15 MDx Colorectal Cancer by Country.....	272
Table 16 Cervical Cancer Testing by Country	274
Table 17 Lung Cancer Testing by Country	276
Table 18 Prostate Testing by Country	278
Table 19 Melanoma Cancer Testing by Country	280
Table 20 MDx Blood by Country	282
Table 21 MDx Companion Dx Development by Country	284
Table 22 MDx Other Cancer Testing by Country	286
Table 23 MDx Instruments by Country.....	289
Table 24 MDx Reagents by Country.....	291

Table 25 Software and Services by Country..... 293

Table 26 MDx Clinical Laboratory by Country..... 296

Table 27 MDx Pharmaceutical by Country 298

Table 28 Research by Country 300

Table 29 2021 Clinical Lab Fee Schedule 306

Table of Figures

Figure 1 Clinical Lab Spending 2014 to 2024	29
Figure 2 Growth in Aging Population	45
Figure 3 Death Rates from Cancer - USA.....	46
Figure 4 Comparing MDx Diagnostic and Traditional Testing	53
Figure 5 Global Market Shares Base Year	250
Figure 6 MDx Market by Cancer - Base vs. Final	252
Figure 7 Cancer Market Base Year	253
Figure 8 Cancer Market Final Year.....	254
Figure 9 MDx Cancer Share by Year.....	255
Figure 10 MDx Cancer Segment Growth Rates	256
Figure 11 MDx Market by Product - Base vs. Final.....	258
Figure 12 Product Market Base Year.....	259
Figure 13 Product Market Final Year	260
Figure 14 MDx Product Share by Year	261
Figure 15 MDx Product Segment Growth Rates.....	262
Figure 16 MDx Market by Place - Base vs. Final.....	264
Figure 17 Place Market Base Year.....	265
Figure 18 Place Market Final Year	266
Figure 19 MDx Place Share by Year	267
Figure 20 MDx Place Segment Growth Rates	268
Figure 21 Breast Cancer Testing Growth.....	271
Figure 22 Colorectal Cancer Testing Growth.....	273
Figure 23 Cervical Cancer Testing Growth.....	275
Figure 24 Lung Cancer Testing Growth.....	277
Figure 25 Prostate Testing Growth	279

Figure 26 Melanoma Cancer Testing Growth 281

Figure 27 Blood Testing Growth 283

Figure 28 Companion Dx Development Growth 285

Figure 29 Other Cancer Testing Growth 287

Figure 30 Instruments Growth 290

Figure 31 Reagents Growth 292

Figure 32 Software and Services Growth 294

Figure 33 Clinical Laboratory Growth 297

Figure 34 Pharmaceutical Growth 299

Figure 35 Research Growth..... 301

Figure 36 FDA Cancer Drug Approvals by Year 303

Figure 37 Clinical Trials for Immunotherapy by Year 304

Figure 38 Pie Chart of Prevalence of Cancer Treatments 305